Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2015 Nov 7

PMID 26545124

Citations 5

Authors

Sherrill L Macura

Melissa J Lathrop

Jiang Gui

Gustavo F Doncel

Susana N Asin

Christiane Rollenhagen

Affiliations

Soon will be listed here.

Abstract

Objectives: The interferon-gamma-induced chemokine CXCL9 is expressed in a wide range of inflammatory conditions including those affecting the female genital tract. CXCL9 promotes immune cell recruitment, activation, and proliferation. The role of CXCL9 in modulating HIV-1 infection of cervicovaginal tissues, a main portal of viral entry, however, has not been established. We report a link between CXCL9 and HIV-1 replication in human cervical tissues and propose CXCL9 as a potential target to enhance the anti-HIV-1 activity of prophylactic antiretrovirals.

Design: Using ex vivo infection of human cervical tissues as a model of mucosal HIV-1 acquisition, we described the effect of CXCL9 neutralization on HIV-1 gene expression and mucosal CD4 T-cell activation. The anti-HIV-1 activity of tenofovir, the leading mucosal pre-exposure prophylactic microbicide, alone or in combination with CXCL9 neutralization was also studied.

Methods: HIV-1 replication was evaluated by p24 ELISA. HIV-1 DNA and RNA, and CD4, CCR5, and CD38 transcription were evaluated by quantitative real-time polymerase chain reaction. Frequency of activated cervical CD4 T cells was quantified using fluorescence-activated cell sorting.

Results: Antibody blocking of CXCL9 reduced HIV-1 replication by decreasing mucosal CD4 T-cell activation. CXCL9 neutralization in combination with suboptimal concentrations of tenofovir, possibly present in the cervicovaginal tissues of women using the drug inconsistently, demonstrated an earlier and greater decrease in HIV-1 replication compared with tissues treated with tenofovir alone.

Conclusions: CXCL9 neutralization reduces HIV-1 replication and may be an effective target to enhance the efficacy of prophylactic antiretrovirals.

Citing Articles

CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B.

Yu X, Chen Y, Cui L, Yang K, Wang X, Lei L Front Microbiol. 2022; 13:1052917.

PMID: 36504808 PMC: 9730243. DOI: 10.3389/fmicb.2022.1052917.

Insertive condom-protected and condomless vaginal sex both have a profound impact on the penile immune correlates of HIV susceptibility.

Mohammadi A, Bagherichimeh S, Choi Y, Fazel A, Tevlin E, Huibner S PLoS Pathog. 2022; 18(1):e1009948.

PMID: 34982799 PMC: 8769335. DOI: 10.1371/journal.ppat.1009948.

Inflammation, HIV, and Immune Quiescence: Leveraging on Immunomodulatory Products to Reduce HIV Susceptibility.

Cromarty R, Archary D AIDS Res Treat. 2020; 2020:8672850.

PMID: 33178456 PMC: 7609152. DOI: 10.1155/2020/8672850.

The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression.

Yin X, Wang Z, Wu T, Ma M, Zhang Z, Chu Z J Transl Med. 2019; 17(1):417.

PMID: 31836011 PMC: 6909626. DOI: 10.1186/s12967-019-02172-3.

Modulation of HIV replication in monocyte derived macrophages (MDM) by steroid hormones.

Devadas K, Biswas S, Ragupathy V, Lee S, Dayton A, Hewlett I PLoS One. 2018; 13(1):e0191916.

PMID: 29373606 PMC: 5786332. DOI: 10.1371/journal.pone.0191916.

References

Yao X, Omange R, Henrick B, Lester R, Kimani J, Ball T . Acting locally: innate mucosal immunity in resistance to HIV-1 infection in Kenyan commercial sex workers. Mucosal Immunol. 2013; 7(2):268-79. DOI: 10.1038/mi.2013.44. View

Gupta P, Collins K, Ratner D, Watkins S, Naus G, Landers D . Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol. 2002; 76(19):9868-76. PMC: 136513. DOI: 10.1128/jvi.76.19.9868-9876.2002. View

Thapa M, Welner R, Pelayo R, Carr D . CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J Immunol. 2008; 180(2):1098-106. PMC: 2185792. DOI: 10.4049/jimmunol.180.2.1098. View

Merbah M, Introini A, Fitzgerald W, Grivel J, Lisco A, Vanpouille C . Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am J Reprod Immunol. 2011; 65(3):268-78. PMC: 3184648. DOI: 10.1111/j.1600-0897.2010.00967.x. View

Moreira C, Venkatesh K, DeLong A, Liu T, Kurpewski J, Ingersoll J . Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis. 2009; 49(6):991-2. PMC: 2730467. DOI: 10.1086/605540. View

Shacklett B . Cell-mediated immunity to HIV in the female reproductive tract. J Reprod Immunol. 2009; 83(1-2):190-5. PMC: 2787994. DOI: 10.1016/j.jri.2009.07.012. View

Card C, Ball T, Fowke K . Immune quiescence: a model of protection against HIV infection. Retrovirology. 2013; 10:141. PMC: 3874678. DOI: 10.1186/1742-4690-10-141. View

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

Pudney J, Quayle A, Anderson D . Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005; 73(6):1253-63. DOI: 10.1095/biolreprod.105.043133. View

10.

Lisco A, Introini A, Munawwar A, Vanpouille C, Grivel J, Blank P . HIV-1 imposes rigidity on blood and semen cytokine networks. Am J Reprod Immunol. 2012; 68(6):515-21. PMC: 3493688. DOI: 10.1111/aji.12015. View

11.

Mogensen T, Melchjorsen J, Larsen C, Paludan S . Innate immune recognition and activation during HIV infection. Retrovirology. 2010; 7:54. PMC: 2904714. DOI: 10.1186/1742-4690-7-54. View

12.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

13.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

14.

Chakrabarti L, Boucherie C, Bugault F, Cumont M, Roussillon C, Breton G . Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2014; 28(11):1593-602. DOI: 10.1097/QAD.0000000000000311. View

15.

Shen L, Guyre P, Anderson C, Fanger M . Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG. J Immunol. 1986; 137(11):3378-82. View

16.

Shen R, Richter H, Clements R, Novak L, Huff K, Bimczok D . Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J Virol. 2009; 83(7):3258-67. PMC: 2655566. DOI: 10.1128/JVI.01796-08. View

17.

Jakobsen M, Olagnier D, Hiscott J . Innate immune sensing of HIV-1 infection. Curr Opin HIV AIDS. 2014; 10(2):96-102. DOI: 10.1097/COH.0000000000000129. View

18.

Greenhead P, Hayes P, WATTS P, Laing K, Griffin G, Shattock R . Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol. 2000; 74(12):5577-86. PMC: 112045. DOI: 10.1128/jvi.74.12.5577-5586.2000. View

19.

Whiting D, Hsieh G, Yun J, Banerji A, Yao W, Fishbein M . Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol. 2004; 172(12):7417-24. DOI: 10.4049/jimmunol.172.12.7417. View

20.

Allers K, Fehr M, Conrad K, Epple H, Schurmann D, Geelhaar-Karsch A . Macrophages accumulate in the gut mucosa of untreated HIV-infected patients. J Infect Dis. 2013; 209(5):739-48. DOI: 10.1093/infdis/jit547. View